M1003 Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy

Short descriptor: Tb scr 12 mo pri fst bio dz

✓ Active HCPCS Level II 2026
Open M1003 in the app →

Look up M1003 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.

M1003 is the HCPCS Level II code for Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy (2026). It belongs to Section M — Medical Services. Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Not separately priced by Part B.

Classification & CMS Attributes

Medicare Coverage
Carrier judgment (code C)
Part B Pricing
Not separately priced by Part B (indicator 00)
Type of Service
Medical care
Effective Date
2023-01-01
2026 Maintenance
No change this year

References

Cite This Page

Reference M1003 with the canonical source and edition:

M1003 — Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/M1003

Canonical URL: https://icd10codingpro.com/hcpcs-codes/M1003

Related Codes in Section M

Browse all HCPCS Level II sections →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2026-01-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial